Chen Jianlin, Wu Lihua, Sun Yifan, Luo Changjun, Chen Xianhua, Wu Lihong, Ding Junping, Pan Gangxi, Han Chaowen, Wu Zijuan, Shen Yongqi
Department of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, Guangxi 545007, P.R. China.
Department of Digestive Internal Medicine, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, Guangxi 545007, P.R. China.
Oncol Lett. 2020 Nov;20(5):254. doi: 10.3892/ol.2020.12117. Epub 2020 Sep 18.
The present study determined the levels of plasma biomarkers in patients with gastric carcinoma (GC) and investigated their clinical significance and diagnostic value. Between April 2014 and December 2018, 90 patients with GC, 90 patients with precancerous lesions (Pre) and 45 healthy controls (NC) were recruited from the Affiliated Liutie Central Hospital of Guangxi Medical University. Five markers were measured: microRNA-650 (miRNA-650; using reverse transcription-quantitative polymerase chain reaction), and carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA211 and CA50 using electrochemiluminescence. Circulating markers were all upregulated in patients with GC (P<0.05), and CA211 and CA50 were significantly increased in patients with Pre. The miRNA-650 and CA211 had an area under the curve (AUC) of 0.700 (moderate) and 0.866 (high), respectively, in the diagnosis of GC. Differentiation of GC from Pre yielded an AUC of 0.665 (low) and 0.708 (moderate), respectively. The combination model of miRNA-650 and CA211 showed an appropriate value of AUC (0.887) to discriminate the GC patients from the healthy subjects with a sensitivity and specificity of 82.5 and 97.7%. Additionally, differentiating GC from Pre yielded an AUC of 0.767 with a sensitivity of 57.1% and a specificity of 95%, respectively. In terms of clinicopathological features, the expression of miRNA-650 and CA211 in plasma was not associated with the patients' age, sex, Tumor-Node-Metastasis stage, or histological type. In conclusion, plasma miRNA-650 and CA211 is a promising and powerful non-invasive marker for the detection of GC.
本研究测定了胃癌（GC）患者血浆生物标志物水平，并探讨其临床意义及诊断价值。2014年4月至2018年12月期间，从广西医科大学附属柳铁中心医院招募了90例GC患者、90例癌前病变（Pre）患者和45例健康对照（NC）。检测了5种标志物：采用逆转录定量聚合酶链反应检测微小RNA-650（miRNA-650），采用电化学发光法检测癌胚抗原（CEA）、糖类抗原（CA）125、CA211和CA50。GC患者的循环标志物均上调（P<0.05），Pre患者的CA211和CA50显著升高。miRNA-650和CA211在GC诊断中的曲线下面积（AUC）分别为0.700（中等）和0.866（高）。GC与Pre的鉴别诊断AUC分别为0.665（低）和0.708（中等）。miRNA-650和CA211的联合模型显示，区分GC患者与健康受试者的AUC值合适（0.887），灵敏度和特异度分别为82.5%和97.7%。此外，区分GC与Pre的AUC为0.767，灵敏度为57.1%，特异度为95%。在临床病理特征方面，血浆中miRNA-650和CA211的表达与患者的年龄、性别、肿瘤-淋巴结-转移分期或组织学类型无关。总之，血浆miRNA-650和CA211是检测GC有前景且强大的非侵入性标志物。
